Overview of Melcam

Property	Description
Active ingredient	Meloxicam
Form	Tablet, Capsule, Suspension, Suppository, Injectable solution
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose	Symptomatic relief of pain, inflammation, and fever
Origin	Synthetic, Oxicam derivative

Melcam is a widely recognized brand name for a synthetic medicinal entity primarily used for its anti-inflammatory and pain-relieving properties, consistently recognized as belonging to the established pharmacological class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The sole active ingredient is Meloxicam, an established synthetic compound that falls under the structural category of an Oxicam derivative. The clinical recognition of Meloxicam supports its purpose in providing general, systemic symptomatic relief for discomfort characterized by pain, inflammation, and elevated body temperature.

What Type of Medicine is Melcam (Meloxicam)?

Melcam is formally classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) that acts as an analgesic and anti-inflammatory agent. The active substance, Meloxicam, is a single-component, synthetic molecule with the empirical chemical formula C14H13N3O4S2. Meloxicam is distinguished within the broader NSAID category by its characteristic as a preferential Cyclooxygenase-2 (COX-2) selective inhibitor. This feature is important as pharmacological studies indicate this selectivity aims to concentrate the anti-inflammatory effect at the site of inflammation.

Primary Role and Therapeutic Purpose

The overarching therapeutic purpose of Meloxicam is to diminish the pain and heat associated with the body's inflammatory response by acting directly on the chemical mediators involved. Meloxicam achieves effective relief by inhibiting the production of prostaglandins, the biological signals responsible for triggering pain sensation and localized swelling. This function supports the symptomatic management of processes driven by these mediators, allowing it to act as an effective general antipyretic (fever reducer) and anti-inflammatory agent.

Regulatory References

Meloxicam - LiverTox - NIH

What side effects are possible with Melcam?

Official Safety Profile and Adverse Reactions

Meloxicam's official safety profile, as documented in regulatory texts, is defined by mandatory warnings concerning the risk of serious adverse events associated with its classification as an NSAID.

Serious Regulatory Safety Alerts

Official labeling documents highlight the documented potential for two major categories of serious adverse reactions:

Serious Cardiovascular (CV) Thrombotic Events: This includes the documented risk of serious, sometimes fatal, events such as myocardial infarction (heart attack) and stroke. This risk may increase with longer periods of use.
Serious Gastrointestinal (GI) Adverse Events: This involves the documented risk of GI tract bleeding, ulceration, and perforation, which can occur without warning symptoms and may be fatal.

Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.

Frequency-Classified Adverse Reactions

Side effects are categorized based on their reported frequency in clinical use, according to regulatory standards:

Classification	Examples of Documented Effects
Common	Gastrointestinal disturbances, such as dyspepsia, nausea, vomiting, abdominal pain, and diarrhea.
Uncommon	Headache, dizziness, fluid retention (edema), hypertension, and anemia.
Rare	Palpitations, gastritis, gastrointestinal haemorrhage, mood disturbances, and visual disturbances.

Population-Specific Safety Statements

Official documents detail specific safety considerations for certain groups. Older adults are documented to be at greater risk for serious CV and GI adverse events. Use is restricted in individuals with severe, non-dialyzed hepatic or renal impairment. Furthermore, the label restricts use beginning at the 30th week of pregnancy due to documented risks to the fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Overdose Information

In the event of taking more than the prescribed dose of Melcam, immediate medical attention is essential. While the majority of patients with acute overdose may remain asymptomatic or experience only minor self-limiting gastrointestinal symptoms, serious clinical outcomes have been documented.

Documented Overdose Presentations

Symptoms of an overdose may include nausea, vomiting, epigastric pain, and drowsiness. More severe presentations that affect multiple systems can include gastrointestinal bleeding, acute renal failure, convulsions, respiratory depression, cardiovascular collapse, and cardiac arrest.

Required Emergency Actions

If an overdose is suspected, contact your health care provider or your local Poison Control Centre immediately. If the patient has collapsed, has had a seizure, has trouble breathing, or cannot be awakened, call emergency services immediately.

Treatment procedures for a medical professional may include gastric lavage followed by the administration of activated charcoal to reduce absorption. Cholestyramine may be used to accelerate the elimination of the drug from the body. Individuals with pre-existing heart conditions or gastrointestinal issues are noted to be at a higher risk of significant health complications from an overdose.

Therapeutic Uses of Melcam

What Melcam Treats: Main Uses and Benefits

Melcam is commonly used in situations involving certain distressing symptoms related to inflammatory or irritative states that interfere with daily functioning. It is generally applied across domains where additional symptomatic support is needed.

Types of Relief and Scenarios of Use

This medication is generally relevant in conditions where functional stability becomes affected, often presenting with systemic or localized discomfort. It is used to help manage symptoms related to physical discomfort, functional stress, and acute joint tenderness. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as phases of temporary worsening or flare-ups.

The application is often relevant for easing symptoms that interfere with daily functioning. It helps address symptom clusters that may become intense or disruptive, especially those associated with inflammatory processes, joint stiffness, and physical discomfort. It offers symptomatic relief that may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Symptom Support for Mobility Melcam is relevant for managing symptoms that interfere with daily comfort, particularly physical stiffness and reduced mobility, supporting patients during episodes of heightened discomfort.

Regulatory References

National Library of Medicine DailyMed overview

Eligibility and Restrictions for Use

Official Eligibility Profile for Melcam (Meloxicam)

Melcam is permitted for use in adults to manage the symptoms of Osteoarthritis and Rheumatoid Arthritis. Pediatric use is established only for treating Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age and older, with use in children under 2 years being not established.

Populations for Whom Use is Contraindicated

Melcam is contraindicated and must not be used in specific groups, including:

Contraindicated Group	Restriction Basis
Aspirin-Sensitive Asthma	History of asthma or allergic reactions after taking aspirin or other NSAIDs.
CABG Surgery	For treatment of peri-operative pain after Coronary Artery Bypass Graft surgery.
Late Pregnancy	Women at 30 weeks gestation and later (third trimester).
Active GI Disease	Patients with active peptic ulceration, hemorrhage, or bleeding disorders.

Conditions Requiring Restricted Use

Use is restricted or requires caution for patients with specific health conditions. The medicine is not recommended for those with severe renal impairment (non-dialyzed) or severe heart failure. Patients with end-stage renal disease on hemodialysis have a strictly limited maximum daily dosage. Use should be limited between 20 and 30 weeks of pregnancy due to risks of fetal renal dysfunction. Older adults are at a greater risk for serious gastrointestinal events and require careful consideration.

What should I know about interactions with other medicines?

Melcam’s official interaction profile, documented by government regulators, centers on both pharmacodynamic and pharmacokinetic effects. A primary interaction restriction dictates that co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin, is not generally recommended and must be avoided due to a significantly increased risk of serious gastrointestinal adverse events.

Pharmacodynamic interactions involve an elevated risk of bleeding or ulceration when Melcam is combined with medicines that affect hemostasis, such as Anticoagulants (e.g., Warfarin), Antiplatelet Agents, Corticosteroids, and certain antidepressants like Selective Serotonin Reuptake Inhibitors (SSRIs). Melcam may also diminish the documented antihypertensive effect of ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Diuretics. These cardiovascular and renal interactions pose a greater documented risk of functional renal failure in elderly patients and those with volume depletion.

In terms of pharmacokinetic outcomes, Melcam can significantly increase the plasma concentrations of co-administered medicines, including Lithium and Methotrexate, a factor that requires caution due to potential toxicity. Conversely, Cholestyramine is documented to accelerate the elimination of Melcam. A specific interaction-related restriction applies to the Melcam oral suspension, which is associated with a risk of intestinal necrosis when co-administered with Sodium Polystyrene Sulfonate. The substance interaction profile includes Alcohol, which is officially documented to increase the risk of stomach bleeding.

Mechanism of Action

How Melcam Works (Mechanism of Action)

Melcam primarily exerts its action through the non-covalent, reversible inhibition of the Cyclooxygenase-2 (COX-2) enzyme, demonstrating a preferential affinity for this isoform over COX-1. This molecular interaction occurs at the enzyme’s active site, physically blocking its catalytic function.

The inhibition of COX-2 directly interrupts the Arachidonic Acid Cascade, a key biochemical pathway. This interruption prevents the conversion of arachidonic acid into pro-inflammatory and pyretic prostaglandins, leading to a significant reduction in the synthesis and release of these potent mediators .

At a systemic level, this mechanism leads to a physiological adjustment by altering the body's response systems. The reduction of peripheral prostaglandin activity limits the sensitization of nerve endings and restricts changes in microvasculature associated with irritation. Furthermore, the molecular blockade centrally affects the hypothalamus, modifying the signaling pathways involved in thermal regulation.

Dosage and Administration Information

How to Use Melcam: Official Administration Guidelines

Melcam (meloxicam) is officially administered via oral and intravenous (IV) routes, with instructions governing the dose, frequency, and specific handling requirements. The fundamental use principle across all approved forms is to use the lowest effective dose for the shortest possible duration.

Official Dosing and Frequency

Melcam is a once-daily medication across all standard adult administration routes.

Administration Route	Standard Adult Dose (Once Daily)	Maximum Adult Dose
Oral Tablet/Suspension	Starting dose: 7.5 mg	15 mg
Oral Capsule	Starting dose: 5 mg	10 mg
Intravenous (IV) Injection	30 mg	30 mg

Administration and Procedural Rules

Timing of Intake: Oral forms (tablets, capsules, suspension) may be taken without regard to the timing of meals.
Preparation: The oral suspension must be shaken gently before measuring and administration.
IV Procedure: The injectable solution must be given as an intravenous bolus injection over a period of 15 seconds. Patients must be well hydrated prior to IV administration.
Non-Interchangeability: Different oral formulations of meloxicam (e.g., tablet vs. capsule) are not substitutable with each other, even if they have the same milligram strength.
Missed Dose: If a dose is missed, standard instructions specify that only the next scheduled dose should be taken at the regular time; the dose should not be doubled to compensate.

Population-Specific Adjustments

Renal Impairment: For patients undergoing hemodialysis, the maximum daily oral dose is restricted to 7.5 mg (tablet/suspension) or 5 mg (capsule).
Pediatrics: The dose for pediatric patients (≥ 2 years of age) is based on body weight, at 0.125 mg/kg once daily, not to exceed 7.5 mg per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Melcam

Melcam (Meloxicam) was evaluated in research exploring symptoms related to inflammatory conditions. The existing research is primarily based on formal clinical trials, including randomized controlled trials (RCTs), comparative studies against other treatments, and systematic reviews. The goal of this research was to explore how symptoms change over defined time periods across different patient groups.

Evidence Base for Osteoarthritis (OA) Symptoms

Research exploring the use of Melcam for the symptomatic management of Osteoarthritis (OA) was evaluated in numerous short-term and intermediate-term randomized controlled trials. These studies examined adult patient populations, including older adults. The outcomes measured were primarily patient-reported outcomes describing perceived discomfort, such as changes in pain intensity, and assessments of outcomes reflecting daily functioning or activity level, like joint stiffness scores. Studies report patterns observed in the studies related to discomfort and function over several weeks or months. The research base for Melcam in conditions characterized by fluctuating or episodic manifestations like OA is based on evidence consistently described as High-level in regulatory records. However, existing studies provide limited insight into whether research has explored the long-term progression of the condition or structural changes in the joint itself.

Evidence Base for Rheumatoid Arthritis (RA) Symptoms

The research involving Melcam for symptomatic changes in Rheumatoid Arthritis (RA) was studied for the adult population in trials focused on conditions involving periods of heightened symptoms. The clinical research examined specific composite measures, such as the ACR 20 criteria, which combines measurements of tender and swollen joints, along with physician and patient global assessments. The research contributes to understanding symptom patterns, but data for long-term joint damage or progression over many years remain insufficient.

Evidence in Special Populations

Specific research was studied for the symptomatic management of Juvenile Idiopathic Arthritis (JIA) in pediatric patients. These studies provide context but not individual predictions for this specific population. Outside of the JIA indication, data for certain groups remain insufficient, including research exploring other specific patient subgroups.

Key Studies & References Meloxicam: DailyMed Product Information

Frequently Asked Questions (FAQ)

Common questions about Melcam (FAQ)

Q: What is the difference between Melcam and other common pain relievers?

Melcam is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) that is described as having a preferential effect on the COX-2 enzyme. This characteristic is what distinguishes it from non-selective NSAIDs, which affect both COX-1 and COX-2 enzymes.

Q: Is Melcam safe for people with stomach issues?

Official documents state that Melcam is contraindicated (must not be used) in patients who have active gastrointestinal problems, such as a peptic ulcer, bleeding, or hemorrhage. It is documented to carry a risk of serious GI adverse events like bleeding or perforation.

Q: Can Melcam be taken with alcohol?

Regulatory documents state that consuming alcohol while using Melcam is associated with an increased risk of stomach bleeding ( GI events). Official guidance emphasizes this risk and does not generally recommend co-administration.

Q: Is Melcam safe to use during pregnancy or breastfeeding?

Melcam is contraindicated (must not be used) in the third trimester of pregnancy (at 30 weeks gestation and later). Regulatory information also indicates that Meloxicam may pass into breast milk, and use during this period should be considered in light of this information.

Q: Is Melcam used for children or adolescents?

Melcam is officially approved for the symptomatic management of Juvenile Idiopathic Arthritis in patients who are 2 years of age and older. Official labeling states that use for other general pediatric conditions is not established.

Q: What does Melcam do to the body to relieve symptoms?

Melcam works by affecting the body's natural processes that create prostaglandins, which are chemical mediators responsible for signaling pain, inflammation, and fever. The reduction of these mediators is the mechanism by which relief may be observed.

Q: Does Melcam cause weight gain or loss?

Fluid retention (edema), which may lead to some weight change, is documented as an uncommon adverse reaction in the official product information. This is an effect observed with some NSAIDs.

Q: Can Melcam affect mood or energy levels?

Mood disturbances are documented in regulatory texts as a rare adverse reaction associated with Melcam. Other documented central nervous system effects, such as dizziness, are classified as uncommon.

Q: Does Melcam have a risk of addiction or dependence?

Melcam is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a narcotic or a federally controlled substance and does not have a documented risk of addiction or dependence.

Q: Is Melcam a controlled substance?

No, Melcam is a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a narcotic or a federally controlled substance under government regulation.

Q: Can Melcam interfere with laboratory blood tests?

While Melcam can affect the body's clotting ability (hemostasis), research cited in official sources indicates that meloxicam, unlike some other NSAIDs, does not significantly interfere with platelet function tests typically performed in a laboratory setting.

Q: Can Melcam cause sun sensitivity?

The medication is documented in official patient information to increase skin sensitivity to UV rays, including sunlight and tanning lamps. This documented effect is referred to as photosensitivity.

Q: Can Melcam be crushed or split?

Official instructions for certain oral formulations state that the tablets must not be cut, crushed, or chewed. It is important to follow the specific administration guidelines provided for the exact form of Melcam being used.

Q: How long does Melcam stay in the body?

According to the pharmacokinetics data in the official prescribing information, Melcam has a documented elimination half-life that typically ranges from 15 to 20 hours. This figure describes the time it takes for half of the drug to be eliminated from the bloodstream.

Q: What is the time frame for expecting Melcam to reach its full effect?

Clinical documents indicate that the medication has a delayed onset of analgesia (pain relief) compared to some immediate-acting medicines. Peak blood concentration, a measure related to effect, is typically reported as achieved around four to five hours after an oral dose.

Q: Why is a specific warning mentioned on the Melcam label?

The official label contains mandatory warnings concerning the documented potential for serious cardiovascular thrombotic events (such as heart attack and stroke) and serious gastrointestinal adverse events (such as bleeding, ulceration, and perforation). These warnings represent the highest level of caution required by regulators for the documented serious risks associated with this class of medicine.

Q: Is Melcam gluten-free or lactose-free?

Regulatory documents for specific formulations of Melcam list lactose monohydrate as an inactive ingredient (excipient) in some versions. Information on other inactive ingredients, such as gluten, generally reports it as not present in the formulation.

Q: What are the signs of a serious side effect from Melcam?

Official patient information details symptoms such as chest pain or sudden shortness of breath (for CV events) and vomiting blood or passing black, tarry stools (for GI events). These symptoms are listed as grounds for seeking immediate medical attention.

Q: How is Melcam metabolized by the body?

Melcam is extensively metabolized (broken down) in the liver by enzymes, primarily CYP2C9 and CYP3A4. This process results in the formation of pharmacologically inactive metabolites, which are then eliminated from the body.

Q: Is it common to feel dizzy or sleepy after taking Melcam?

Dizziness is documented in the official adverse reaction data as an uncommon side effect. Other central nervous system effects, such as drowsiness (feeling sleepy), are classified as rare.

Q: Does Melcam interact with birth control pills?

Official drug interaction information indicates that co-administration with certain types of oral contraceptives, specifically those containing drospirenone, has been documented to potentially increase potassium levels in the blood. This documented interaction is a factor to consider in the context of co-administration.

Q: Does Melcam interact with grapefruit juice?

Information in official regulatory documents generally indicates no clinically significant interaction between Melcam and the consumption of grapefruit juice.

How should Melcam be stored and disposed of?

How to Store and Dispose of Melcam (Meloxicam)

Meloxicam must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). Permitted temperature excursions allow for storage up to 30 C (86 F). The medication must be kept in its original container, tightly closed, and stored away from excess moisture and heat.

Child Safety and Disposal

It is mandatory to store Meloxicam out of the sight and reach of children. Regarding disposal, patients must follow specific instructions provided by their prescription labeling or utilize authorized drug take-back programs. If household disposal is necessary, the unused medicine must be removed from its container, mixed with an undesirable substance like dirt or coffee grounds, sealed in a bag, and then placed in the trash. Disposal into sewers or waterways is generally prohibited.

Melcam